Literature DB >> 18416435

Evaluating competing adverse and beneficial outcomes using a mixture model.

Bryan Lau1, Stephen R Cole, Richard D Moore, Stephen J Gange.   

Abstract

A competing risk framework occurs when individuals have the potential to experience only one of the several mutually exclusive outcomes. Standard survival methods often overestimate the cumulative incidence of events when competing events are censored. Mixture distributions have been previously applied to the competing risk framework to obtain inferences regarding the subdistribution of an event of interest. Often the competing event is treated as a nuisance, but it may be of interest to compare adverse events against the beneficial outcome when dealing with an intervention. In this paper, methods for using a mixture model to estimate an adverse-benefit ratio curve (ratio of the cumulative incidence curves for the two competing events) and the ratio of the subhazards for the two competing events are presented. A parametric approach is described with some remarks for extending the model to include uncertainty in the event type that occurred, left truncation in order to allow for time-dependent analyses, and uncertainty in the timing of the event resulting in interval censoring. The methods are illustrated with data from an HIV clinical cohort examining whether individuals initiating effective antiretroviral therapy have a greater risk of antiretroviral discontinuation or switching compared with HIV RNA suppression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18416435      PMCID: PMC2551745          DOI: 10.1002/sim.3293

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  32 in total

1.  The estimation of the probability of developing a disease in the presence of competing risks.

Authors:  J CORNFIELD
Journal:  Am J Public Health Nations Health       Date:  1957-05

2.  Applications of crude incidence curves.

Authors:  E L Korn; F J Dorey
Journal:  Stat Med       Date:  1992-04       Impact factor: 2.373

3.  The era of adherence to HIV therapy.

Authors:  F L Altice; G H Friedland
Journal:  Ann Intern Med       Date:  1998-09-15       Impact factor: 25.391

4.  Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. Adult/Adolescent Spectrum of Disease Group.

Authors:  A D McNaghten; D L Hanson; J L Jones; M S Dworkin; J W Ward
Journal:  AIDS       Date:  1999-09-10       Impact factor: 4.177

5.  Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study.

Authors:  Todd T Brown; Stephen R Cole; Xiuhong Li; Lawrence A Kingsley; Frank J Palella; Sharon A Riddler; Barbara R Visscher; Joseph B Margolick; Adrian S Dobs
Journal:  Arch Intern Med       Date:  2005-05-23

6.  Natural history of HIV infection in the era of combination antiretroviral therapy.

Authors:  R D Moore; R E Chaisson
Journal:  AIDS       Date:  1999-10-01       Impact factor: 4.177

7.  Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir.

Authors:  Mark S Sulkowski; Shruti H Mehta; Richard E Chaisson; David L Thomas; Richard D Moore
Journal:  AIDS       Date:  2004-11-19       Impact factor: 4.177

8.  Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study.

Authors:  Todd T Brown; Xiuhong Li; Stephen R Cole; Lawrence A Kingsley; Frank J Palella; Sharon A Riddler; Joan S Chmiel; Barbara R Visscher; Joseph B Margolick; Adrian S Dobs
Journal:  AIDS       Date:  2005-09-02       Impact factor: 4.177

9.  Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators.

Authors:  R Detels; A Muñoz; G McFarlane; L A Kingsley; J B Margolick; J Giorgi; L K Schrager; J P Phair
Journal:  JAMA       Date:  1998-11-04       Impact factor: 56.272

10.  Class of antiretroviral drugs and the risk of myocardial infarction.

Authors:  Nina Friis-Møller; Peter Reiss; Caroline A Sabin; Rainer Weber; Antonella d'Arminio Monforte; Wafaa El-Sadr; Rodolphe Thiébaut; Stephane De Wit; Ole Kirk; Eric Fontas; Matthew G Law; Andrew Phillips; Jens D Lundgren
Journal:  N Engl J Med       Date:  2007-04-26       Impact factor: 91.245

View more
  9 in total

1.  Inference for mutually exclusive competing events through a mixture of generalized gamma distributions.

Authors:  William Checkley; Roy G Brower; Alvaro Muñoz
Journal:  Epidemiology       Date:  2010-07       Impact factor: 4.822

Review 2.  Applying competing risks regression models: an overview.

Authors:  Bernhard Haller; Georg Schmidt; Kurt Ulm
Journal:  Lifetime Data Anal       Date:  2012-09-26       Impact factor: 1.588

3.  Parametric mixture models to evaluate and summarize hazard ratios in the presence of competing risks with time-dependent hazards and delayed entry.

Authors:  Bryan Lau; Stephen R Cole; Stephen J Gange
Journal:  Stat Med       Date:  2010-11-30       Impact factor: 2.373

4.  Competing risk regression models for epidemiologic data.

Authors:  Bryan Lau; Stephen R Cole; Stephen J Gange
Journal:  Am J Epidemiol       Date:  2009-06-03       Impact factor: 4.897

5.  When to Censor?

Authors:  Catherine R Lesko; Jessie K Edwards; Stephen R Cole; Richard D Moore; Bryan Lau
Journal:  Am J Epidemiol       Date:  2018-03-01       Impact factor: 4.897

6.  Causal inference in the face of competing events.

Authors:  Jacqueline E Rudolph; Catherine R Lesko; Ashley I Naimi
Journal:  Curr Epidemiol Rep       Date:  2020-07-12

7.  Competing risks and the clinical community: irrelevance or ignorance?

Authors:  Michael T Koller; Heike Raatz; Ewout W Steyerberg; Marcel Wolbers
Journal:  Stat Med       Date:  2011-09-23       Impact factor: 2.373

8.  Methods of competing risks flexible parametric modeling for estimation of the risk of the first disease among HIV infected men.

Authors:  Sahar Nouri; Mahmood Mahmoudi; Kazem Mohammad; Mohammad Ali Mansournia; Mahdi Yaseri; Noori Akhtar-Danesh
Journal:  BMC Med Res Methodol       Date:  2020-01-29       Impact factor: 4.615

9.  Missingness in the Setting of Competing Risks: from missing values to missing potential outcomes.

Authors:  Bryan Lau; Catherine Lesko
Journal:  Curr Epidemiol Rep       Date:  2018-03-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.